Harrow Health Adds Two Senior Executives to its Nashville Team
Harrow, Inc. (HROW)
Last harrow, inc. earnings: 11/13 04:21 pm
Check Earnings Report
Company Research
Source: GlobeNewswire
NASHVILLE, Tenn., June 25, 2019 (GLOBE NEWSWIRE) -- Harrow Health, Inc. (NASDAQ: HROW) today announced that it has promoted Dennis Saadeh, PharmD as its Chief of Formulation Strategy and has hired Larry Dillaha, MD as its Chief Medical Officer. Dr. Saadeh, who is a 30-year veteran of pharmaceutical development, has worked with Harrow since January of 2015, including work on over 15 prescription drug products in ophthalmology, and several women’s and men’s health and oncology drug candidates. He will be responsible for Harrow’s existing portfolio of drug candidate formulations and will continue to develop additional drug candidates for its portfolio of businesses. Dr. Dillaha, an experienced clinical physician and a 20-year veteran of the pharmaceutical industry, was previously a senior consultant to Harrow and serves on the board of directors of Melt Pharmaceuticals, a Harrow-founded business developing patented sublingual non-opioid non-IV sedation and pain drug candidates. Dr.
Show less
Read more
Impact Snapshot
Event Time:
HROW
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
HROW alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
HROW alerts
High impacting Harrow, Inc. news events
Weekly update
A roundup of the hottest topics
HROW
News
- Harrow Will Release First Quarter 2024 Financial Results After Market Close on May 13, 2024Business Wire
- Harrow Health, Inc. (NASDAQ: HROW) is now covered by analysts at Craig Hallum. They set a "buy" rating and a $24.00 price target on the stock.MarketBeat
- Melt Pharmaceuticals Closes $24 Million Series B Preferred Stock FinancingBusiness Wire
- Harrow Health, Inc. (NASDAQ: HROW) had its price target lowered by analysts at B. Riley from $30.00 to $26.00. They now have a "buy" rating on the stock.MarketBeat
- Harrow Health, Inc. (NASDAQ:HROW) Q4 2023 Earnings Call Transcript [Yahoo! Finance]Yahoo! Finance
HROW
Earnings
- 11/13/23 - Miss
HROW
Sec Filings
- 4/24/24 - Form 4
- 4/19/24 - Form 4
- 3/28/24 - Form 4
- HROW's page on the SEC website